DelveInsight’s “Malignant Pleural Mesothelioma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Malignant Pleural Mesothelioma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Malignant Pleural Mesothelioma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Malignant Pleural Mesothelioma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Malignant Pleural Mesothelioma: An Overview
Mesothelioma is a rare, aggressive cancer that develops in the lungs, abdomen, or heart lining. Asbestos exposure is the only known cause of malignant mesothelioma. Early symptoms of mesothelioma are similar to those of more common diseases such as pneumonia, the flu, or irritable bowel syndrome. Due to how long mesothelioma takes to develop, symptoms often do not appear until tumors have progressed. Many patients are diagnosed with mesothelioma after exhibiting a persistent cough, pneumonia-like symptoms, or fluid buildup; as this type of cancer can take decades to develop, its symptoms often appear without warning.
The type of mesothelioma can be based on where the tumors develop in the body. Pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma, and testicular mesothelioma are the common types and comprise almost all cases.
Malignant Pleural Mesothelioma (MPM) is a type of cancer that develops in the lungs, the cause of pleural mesothelioma is exposure to asbestos fibers, which are inhaled into the lungs. Mesothelioma usually takes around 20–50 years to develop after a person’s first exposure to asbestos; due to this latency period, the disease usually affects people older than 75.
Malignant Pleural Mesothelioma Market Key Facts
-
In 2021, the US has the largest Malignant Pleural Mesothelioma market size of ~USD 100 million among the 7MM countries.
-
Among the EU4 and the UK, the United Kingdom had the highest market size for Malignant Pleural Mesothelioma in 2021, i.e., ~USD 46 million.
-
In Japan, the market size for Malignant Pleural Mesothelioma was observed to be ~USD 39 million in 2021.
-
As per DelveInsight’s estimates, in the year 2021, there were ~12,300 incident cases of mesothelioma in the 7MM. The total incident cases of MPM were ~10,800 in the 7MM in 2021.
-
The United States, in 2021, accounted for ~17% of the total MPM cases in the 7MM. There were ~1,900 cases of MPM in the US in 2021.
Malignant Pleural Mesothelioma Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Malignant Pleural Mesothelioma pipeline therapies. It also thoroughly assesses the Malignant Pleural Mesothelioma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Malignant Pleural Mesothelioma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Malignant Pleural Mesothelioma Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Malignant Pleural Mesothelioma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Malignant Pleural Mesothelioma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Malignant Pleural Mesothelioma Epidemiology, Segmented as –
-
Total Incident Cases of MPM in Mesothelioma in the 7MM [2019–2032]
-
Histology-specific Incident Cases of MPM in the 7MM [2019–2032]
-
Stage-specific Incident Cases of MPM in the 7MM [2019–2032]
-
Gender-specific Incident Cases of MPM in the 7MM [2019–2032]
-
Age-specific Incident Cases of MPM in the 7MM [2019–2032]
Malignant Pleural Mesothelioma Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Malignant Pleural Mesothelioma market or expected to be launched during the study period. The analysis covers the Malignant Pleural Mesothelioma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Malignant Pleural Mesothelioma drugs based on their sale and market share.
The report also covers the Malignant Pleural Mesothelioma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Malignant Pleural Mesothelioma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Malignant Pleural Mesothelioma Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-market
Malignant Pleural Mesothelioma Therapeutics Analysis
Currently, treatment strategies for Malignant Pleural Mesothelioma include chemotherapy, radiation, and surgery. Sometimes specialists may use a combination of the abovementioned approaches, called multimodal therapy. MPM patients diagnosed in the early stages benefit the most from surgery. The main goal of surgery for Malignant Pleural Mesothelioma is to remove all visible tumors, hoping that chemotherapy and/or radiation can eliminate the residual microscopic disease.
To further improve the treatment scenario, several major pharma and biotech companies are developing therapies for Malignant pleural mesothelioma. Currently, MolMed is leading the therapeutics market with its Malignant pleural mesothelioma drug candidates in the most advanced stage of clinical development.
Malignant Pleural Mesothelioma Companies Actively Working in the Therapeutics Market Include
-
Amphera BV
-
AstraZeneca
-
Hoffmann-La Roche
-
PharmaMar
-
Polaris Pharmaceuticals
-
Sellas Life Sciences Group
-
Targovax
-
TCR2 Therapeutics
And Many Others
Emerging and Marketed Malignant Pleural Mesothelioma Therapies Covered in the Report Include:
-
IMFINZI (durvalumab; MEDI4736): AstraZeneca
-
Lurbinectedin: PharmaMar
-
NGR-TNF: MolMed
-
ONCOS-102: AstraZeneca
-
Pegargiminase: Polaris Pharmaceuticals
-
Pembrolizumab : Merck & Co
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Malignant Pleural Mesothelioma Competitive Intelligence Analysis
4. Malignant Pleural Mesothelioma Market Overview at a Glance
5. Malignant Pleural Mesothelioma Disease Background and Overview
6. Malignant Pleural Mesothelioma Patient Journey
7. Malignant Pleural Mesothelioma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Malignant Pleural Mesothelioma Treatment Algorithm, Current Treatment, and Medical Practices
9. Malignant Pleural Mesothelioma Unmet Needs
10. Key Endpoints of Malignant Pleural Mesothelioma Treatment
11. Malignant Pleural Mesothelioma Marketed Therapies
12. Malignant Pleural Mesothelioma Emerging Drugs and Latest Therapeutic Advances
13. Malignant Pleural Mesothelioma Seven Major Market Analysis
14. Attribute Analysis
15. Malignant Pleural Mesothelioma Market Outlook (In US, EU5, and Japan)
16. Malignant Pleural Mesothelioma Companies Active in the Market
17. Malignant Pleural Mesothelioma Access and Reimbursement Overview
18. KOL Views on the Malignant Pleural Mesothelioma Market
19. Malignant Pleural Mesothelioma Market Drivers
20. Malignant Pleural Mesothelioma Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Hypercoagulability Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Hypercoagulability market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Hypercoagulability market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/